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Background: It has been shown in many solid tumors that the overexpression of the pro-survival Bcl-2 family
members Bcl-2/Bcl-xL and Mcl-1 confers resistance to a variety of chemotherapeutic agents. We designed the BH3
α-helix mimetic JY-1-106 to engage the hydrophobic BH3-binding grooves on the surfaces of both Bcl-xL and Mcl-1.
Methods: JY-1-106–protein complexes were studied using molecular dynamics (MD) simulations and the SILCS
methodology. We have evaluated the in vitro effects of JY-1-106 by using a fluorescence polarization (FP) assay, an XTT
assay, apoptosis assays, and immunoprecipitation and western-blot assays. A preclinical human cancer xenograft model
was used to test the efficacy of JY-1-106 in vivo.
Results: MD and SILCS simulations of the JY-1-106–protein complexes indicated the importance of the aliphatic side
chains of JY-1-106 to binding and successfully predicted the improved affinity of the ligand for Bcl-xL over Mcl-1.
Ligand binding affinities were measured via an FP assay using a fluorescently labeled Bak-BH3 peptide in vitro.
Apoptosis induction via JY-1-106 was evidenced by TUNEL assay and PARP cleavage as well as by Bax–Bax
dimerization. Release of multi-domain Bak from its inhibitory binding to Bcl-2/Bcl-xL and Mcl-1 using JY-1-106 was
detected via immunoprecipitation (IP) western blotting.
At the cellular level, we compared the growth proliferation IC50s of JY-1-106 and ABT-737 in multiple cancer cell lines
with various Bcl-xL and Mcl-1 expression levels. JY-1-106 effectively induced cell death regardless of the Mcl-1
expression level in ABT-737 resistant solid tumor cells, whilst toxicity toward normal human endothelial cells was
limited. Furthermore, synergistic effects were observed in A549 cells using a combination of JY-1-106 and multiple
chemotherapeutic agents. We also observed that JY-1-106 was a very effective agent in inducing apoptosis in
metabolically stressed tumors. Finally, JY-1-106 was evaluated in a tumor-bearing nude mouse model, and was found
to effectively repress tumor growth. Strong TUNEL signals in the tumor cells demonstrated the effectiveness of JY-1-106
in this animal model. No significant side effects were observed in mouse organs after multiple injections.
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Conclusions: Taken together, these observations demonstrate that JY-1-106 is an effective pan-Bcl-2 inhibitor with very
promising clinical potential.
Keywords: Mcl-1, Bcl-xL, Small molecule inhibitor, Cancer, BH3 mimeticBackground
Despite decades of cancer research, the survival rates for
patients with solid tumors have improved only modestly.
Many tumors are unresponsive to conventional therapy
due to the resistance of tumor cells to apoptosis, or pro-
grammed cell death. Since the molecular cloning of Bcl-2
[1], the anti-apoptotic members of the Bcl-2 family, which
include Bcl-2, Bcl-xL and Mcl-1, have been identified as
key regulators of mitochondria membrane potential and
oncogenesis, as well as chemoresistance [2].
Bcl-xL was found to have a unique role in chemo-
resistance in multiple cancers in an NIH Developmental
Therapeutics Program study that determined that high
levels of Bcl-xL protect a variety of cancer cell lines from
70,000 cytotoxic agents [2]. The downregulation of Bcl-xL
has been shown to induce apoptosis and increase chemo-
sensitivity. ABT-737 [3], the most well-known member of
a class of Bcl-2-family targeting compounds, and its orally
active analog ABT-263 [4], have activity as single agents in
a subset of cancers (including multiple myeloma and
small-cell lung cancer) that rely on Bcl-2/Bcl-xL, but not
Mcl-1, for survival.
Because of the overexpression and overlapping functions
of the Bcl-2 family proteins, Mcl-1 can compensate for the
loss of the anti-apoptotic function of Bcl-2/xL. Recent
studies demonstrated that cancer cells rapidly develop
resistance to ABT-737 through the up-regulation of Mcl-1
and that the down-regulation of Mcl-1 restores the sensi-
tivity to ABT-737 [5,6]. Mcl-1 reduction significantly
enhances the sensitivity of cancer cells to ABT-737 and
other chemotherapeutics [6,7]. Hence, these findings
suggest that Mcl-1 overexpression may function as an
additional survival mechanism to protect cancer cells
against conventional therapies.
Although the basic topology of BH3 domain hydro-
phobic binding groove is highly conserved among the
prosurvival Bcl-2 family members such as Bcl-2, Bcl-xL
and Mcl-1 [8], there is a selectivity in binding defined
by the specific pattern of amino acid side chains located
on the α2, α4, and α5 helices [7]. This may explain why
ABT-737 does not exhibit potency against Mcl-1. Be-
cause this hydrophobic groove normally accommodates
the BH3 domain of pro-apoptotic Bcl-2 proteins, it has
been hypothesized that small molecules that bind to this
BH3-binding groove in Bcl-2, Bcl-xL, or Mcl-1 may becapable of blocking their heterodimerization with a
subset of pro-apoptotic members in the Bcl-2 protein
family, such as Bax, Bid, and Bak. This would expand
the pool of free pro-apoptotic effectors and, thus,
induce apoptosis in cancer cells in which overexpressed
Bcl-2, Bcl-xL, or Mcl-1 provide survival cues. Hence,
the development of BH3 mimetics could be a feasible
and clinically effective approach to simultaneously
inhibiting Bcl-2/xL and Mcl-1 functions.
Indeed, several non-peptidic small-molecule BH3 mi-
metics designed to bind key domains in the hydrophobic
BH3-binding groove have already been identified [9,10],
the most extensively studied of which is the previously
mentioned compound ABT-737. An alternative strategy to
the disruption of this protein–protein interaction centers
on the observation that the BH3 domains of the pro-
apoptotic proteins become α-helical upon binding their
anti-apoptotic partners [11]. Accordingly, small-molecules
have been designed to reproduce the relative projections
of key hydrophobic side chains found on one face of the
BH3 α-helix. For example, mimicry of Val74, Leu78, Ile81
(and Ile85) on one face of the Bak-BH3 α-helix has
afforded potent Bcl-xL inhibitors [12]. More recently,
an α-helix mimetic strategy based on a terphenyl scaf-
fold has furnished a “pan-Bcl-2” antagonist, inhibiting
Bcl-2, Bcl-xL and Mcl-1 [13]. However, many of the
BH3 mimetics that potently engage the Bcl-2/Bcl-xL/
Bcl-w sub-class of the anti-apoptotic Bcl-2 proteins
often only weakly inhibit members of the Mcl-1/Bfl-1
sub-class. An effective BH3 mimetic should “neutralize”
both sub-classes, as this is required for apoptosis to occur.
We herein describe the biological characterization
of our novel “pan-Bcl-2” inhibitor JY-1-106, which,
based on a trisarylamide framework, reproduces the
chemical nature and relative spatial projections of
the key hydrophobic side chains on one face of the
BH3 α-helix. JY-1-106 induces cancer cell death regard-
less of the Mcl-1 expression levels through intrinsic
apoptosis pathways, and sensitizes tumor cells to che-
motherapeutic agents and to metabolic stress. Further-
more, we demonstrate that JY-1-106 inhibits tumor
growth in a lung cancer xenograft model, and, therefore,
that α-helix mimicry based on a trisarylamide scaffold
warrants further investigation towards the development
of novel chemotherapeutics.
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Both “faces” of the BH3 α-helix contribute to the
stabilization of the protein–protein complex upon
docking with the BH3-binding groove. In addition to
the previously mentioned hydrophobic residues on one
face of the Bak-BH3 α-helix, Arg76 and Asp83 located
on the other face of the helix are also important for
binding [11]. Thus, towards the development of potent,
pan-Bcl-2 antagonists, we wished to design amphipathic
α-helix mimetics that would achieve more superior α-helix
mimicry than ever reported before, as well as, potentially,
better selectivity profiles against non-Bcl-2 proteins. We
reasoned that this process would be accelerated by
selecting and modifying a functional α-helix mimetic from
the literature. Compounds based on an oligoamide-
foldamer strategy appeared excellent candidates, primarily
owing to their straightforward chemical syntheses [14]. A
structure–activity relationship analysis of the backbone of
a previously reported oligoamide-based α-helix mimetic
designed to inhibit Bcl-xL [14] led to the discovery of the
novel compound JY-1-106 (Figure 1A) with even greater
affinity for Bcl-xL [15]. Although only the second most
potent compound of the congeners synthesized, the aque-
ous solubility of JY-1-106 was, in our hands, greater than
that of the most potent derivative, and so JY-1-106 was
selected for further biological characterization.
Computational analyses of the binding of JY-1-106 to
Bcl-xL and Mcl-1
Molecular details of the interactions of JY-1-106 with
Bcl-xL and Mcl-1 were obtained by modeling inhibitorFigure 1 The computational design of JY-1-106. (A) Chemical structure
maps of JY-1-106 (forward orientation) side chain carbon atoms (green) alo
atoms (orange) overlaid on a representative conformation of JY-1-106 dete
fluctuations of residues lining the binding pocket for Bcl-xL (D) and Mcl-1 (
orientations.binding with these proteins based on the crystallographic
orientations of the bound peptides, followed by MD simu-
lations. In addition, the SILCS methodology [16,17] was
applied to quantify the energetic differences associated
with binding to the two proteins and between the binding
of JY-1-106 and its analog JY-1-106a (Figure 1A) to the
proteins. Analysis of the MD sampled complex confor-
mations suggested that the JY-1-106 binds to Bcl-xL
and Mcl-1 in the same way as Bak, Bax and other BH3
peptides. From the MD simulations, 3D probability
distributions of the carbon atoms in the three aliphatic
side chains of JY-1-106 (forward orientation) were
obtained and are presented in Figures 1B and 1C for
Bcl-xL and Mcl-1, respectively, along with the posi-
tions of the corresponding amino acid side chains from
the BH3-protein crystal structures and a representative
orientation of JY-1-106 from the MD simulation. The
hydrophobic interactions between the BH3 peptide
and the protein were reproduced by JY-1-106 quite
well as indicated by the overlap between the probability
distributions and the experimental BH3 peptide side chain
positions.
To further examine the role of the aliphatic functional
groups of JY-1-106 in protein binding, simulations of
JY-1-106a (Figure 1A) were also performed to compare
with simulations of JY-1-106. For Bcl-xL, much larger
flexibilities occur for residues between 105 and 120
when JY-1-106a is bound versus JY-1-106 (Figure 1D),
and higher flexibilities for residues between 250 and
260 also occur for Mcl-1 when JY-1-106a is present
(Figure 1E). Previously, it was observed that residues
between 105 and 120 of Bcl-xL have higher flexibilitiess of JY-1-106 and its analog JY-1-106a. (B and C) Probability distribution
ng with the corresponding crystallographic peptide side chain heavy
rmined from the MD simulation for both Bcl-xL (B) and Mcl-1 (C). RMS
E), with JY-1-106 and JY-1-106a in both the forward and backward
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[18]. Additionally, residues between 250 and 260 have
higher flexibilities when the bound peptide is absent for
Mcl-1, consistent with previous observations [12]. The
RMSF plots in our current study suggest that the pro-
tein structure is closer to the apo-form when JY-1-106a
is present and closer to the peptide bound form when
JY-1-106 is present for both Bcl-xL and Mcl-1. This
emphasizes the role of the hydrophobic side chains in
JY-1-106 for binding.
Subsequent calculations applied the SILCS method-
ology [16,17] to estimate binding affinities based on lig-
and grid free energy (LGFE) scores were calculated to
quantify the binding of JY-1-106 to the two proteins
using three different approaches (Table 1). The two less
computationally demanding LGFE approaches give
similar LGFE scores: approximately −10 kcal/mol for
JY-1-106 binding to Bcl-xL and about −7 kcal/mol for
Mcl-1. LGFE scores calculated using the conformations
from the 50 ns MD simulations give more favorable
scores of approximately −14 and −8 kcal/mol for Bclxl
and Mcl-1, respectively. Thus, the SILCS methodology
predicts the JY-1-106 to interact more favorably with



















Difference, Mcl-1 - Bcl-xL
F 2.1 0.9
B 2.5 -0.1
Total Ligand Grid Free Energies (LGFE, kcal/mol) for JY-1-106 binding to Bcl-xL and
simulation approaches along with LGFE group contributions summed over the arom
Results are presented for both forward (F) and backward (B) orientations of JY-1-10
paranthesis for the total LGFEs are standard errors.depending on the methodology, consistent with the ex-
perimental analysis presented below. Notably, the LGFE
scores obtained for forward and backward orientations
of JY-1-106 are similar, suggesting that both binding ori-
entations are possible.
Additional analysis involved calculations of the LGFE
scores for the aromatic and aliphatic functional groups
in JY-1-106 for Bcl-xL and Mcl-1 to identify the
regions of the inhibitors that 1) make the largest con-
tribution to binding and 2) contribute to the relative
binding affinities. Results in Table 1 show the LGFE for
the aromatic and aliphatic groups; contributions from
the hydrogen bond donors and acceptors were not
significant (i.e. < 0.1 kcal/mol) and are not shown. The
binding affinities are dominated by the aromatic
groups in all but one case, though both the aromatic
and aliphatic groups are making favorable contribu-
tions to binding. Concerning the relative binding to
Bcl-xL versus Mcl-1, the aromatic groups are leading
the enhanced binding to Bcl-xL in the majority of the
modeling cases. These results suggest that modifica-
tions of the aromatic regions of JY-1-106 could be used
to both improve affinity as well as alter the relative
affinities for Bcl-xL versus Mcl-1.Langevin dynamics Explict solvent MD
-10.6 (4.2) -13.8 (4.1)
-10.6 (4.0) -15.8 (2.7)
-7.2 (2.3) -8.7 (1.5)
-7.0 (2.2) -7.5 (2.2)
3.4 5.1
3.6 8.3
Langevin dynamics Explict Solvent MD
Aromatic Aliphatic Aromatic Aliphatic
-5.9 -4.4 -11.3 -2.5
-7.2 -3.3 -12.4 -3.5
-4.9 -2.2 -4.0 -4.7
-5.5 -1.5 -5.3 -2.2
1.0 2.2 7.3 -2.2
1.7 1.8 7.1 1.3
Mcl-1 based on the minimization, Langevin Dynamics and Explicit Solvent MD
atic and aliphatic functional groups for Bcl-xL and Mcl-1.
6 and differences (Mcl-1 – Bcl-xL) are presented for all values. Values in
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anti-apoptotic proteins in vitro and in tumor cells
The modeling studies described above suggest that JY-
1-106 binds to the anti-apoptotic proteins Bcl-xL and
Mcl-1 in a similar fashion to that of the Bak-BH3 α-helix.
We speculated that if JY-1-106 binds anti-apoptotic
proteins in this way, then it should disrupt their binding
to pro-apoptotic proteins. To evaluate this possibility,
we first determined whether JY-1-106 disrupts the binding
of Bcl-xL and Mcl-1 to Bak in vitro using fluorescence
polarization (FP) assays [19]. Results show that JY-1-106
inhibits the interaction between a FITC-labeled Bak-BH3
peptide and Bcl-xL or Mcl-1 in a dose-dependent manner
with IC50 values of 394 ± 54 nM [15] and 10.21 ± 0.83 μM
(Figure 2A), respectively. The experimental Ki is about
10 times larger for Mcl-1 (Ki: Bcl-xL = 179 ± 24 nM;
Mcl-1 = 1.79 ± 0.15 μM, which, in terms of binding free
energy, is about a 1.4 kcal/mol difference, in satisfactory
agreement with the above calculations that indicate JY-
1-106 binds more favorably to Bcl-xL than Mcl-1 by 2
or more kcal/mol.
IP western blotting was next applied to determine
whether JY-1-106 could effectively disrupt the binding
between Bak and anti-apoptotic proteins Bcl-xL and
Mcl-1 in tumor cells. REN cells, a Bcl-xL and Mcl-1
overexpressing tumor cell line, were exposed to vehicle
control, ABT-737 and JY-1-106, respectively. Endogenous
Bcl-xL protein in these cells was immunoprecipitated and
its binding to Bak was determined using anti-Bak western
blotting. As demonstrated in Figure 2B, JY-1-106 as well
as ABT-737 can effectively displace Bak from its inhibitory
binding with Bcl-xL. The reverse IP western blotting
approach, which was to immunoprecipitate Bak and
immunoblot using Bcl-xL antibodies, further demonstrated
that JY-1-106 can effectively disrupt the Bak–Bcl-xL
protein–protein interaction. A similar blotting approach
was adopted to determine the effectiveness of JY-1-106
at inhibiting the binding between Mcl-1 and Bak. As
demonstrated in Figure 2C, JY-1-106, but not ABT-737,
can successfully displace Bak from Mcl-1. Hence, JY-1-106
can function as a pan-Bcl-2 inhibitor.
JY-1-106 induces cell death in cancer cells regardless of
the Mcl-1 expression level
To determine whether JY-1-106 can induce cell growth
inhibition in cancer cells with high Mcl-1 expression,
the baseline protein expressions of Bcl-xL and Mcl-1 in
multiple cell lines were initially examined via western
blotting (Figure 3A). The results demonstrated the con-
current expression of both Mcl-1 and Bcl-xL in most of
the lines, corroborating the immunostaining results in
both lung and colon tumor tissues shown in Additional
file 1: Figure S1. The cell lines were subsequently
exposed to various chemotherapeutic agents at differentdoses, including cisplatin, SAHA, ABT-737 and JY-1-106.
As demonstrated in Figure 3B, all the cancer cell lines that
express relatively high levels of Bcl-xL and Mcl-1, and
the H23 line, which shows strong Mcl-1 expression and
low Bcl-xL expression, demonstrate resistance to vari-
ous chemotherapy agents including cisplatin, SAHA
and ABT-737. Conversely, JY-1-106 causes significant
tumor cell growth inhibition in these chemotherapy-
resistant cancer cell lines. Most interestingly, JY-1-106
is very effective in the I45 BR and DLD-1 BR cell lines,
which are ABT-737 resistant cells established from
parental I45 and DLD-1 cells.
To further assess whether JY-1-106 can overcome
the Mcl-1 overexpression-related resistance to Bcl-xL
inhibition, DLD-1BR and REN cells were transfected
with control siRNAs or Mcl-1 siRNAs and then exposed
to ABT-737. As shown in Figure 3C, after Mcl-1 reduction
and ABT-737 treatment, the growth proliferation IC50
values for ABT-737 in these cells were improved to
levels similar to those of JY-1-106 in untransfected cells
(Figure 3B). Given that ABT-737 is a more potent
inhibitor of Bcl-xL in vitro than JY-1-106, these data
further suggest that the superior cytotoxicity of JY-1-106
is due to its pan-Bcl-2 specificity. To evaluate the
potential toxicity against normal human cells, normal
human microvascular endothelial cells (HMVECs) were
exposed to various doses of JY-1-106. As demonstrated
in Figure 3D, JY-1-106 at 5 μM has limited toxicity
against HMVECs. At 20 μM, JY-1-106 caused less than
20% growth inhibition in these normal cells. TUNEL
assay results demonstrated that even at 20 μM, JY-1-106
does not cause apoptosis in HMVECs (data not shown).
JY-1-106 induces apoptosis via intrinsic apoptosis
pathway
To determine if the observed JY-1-106-induced cell growth
inhibition occurred by autophagy, cultured I45 EGFP-LC-
3β and A549 EGFP-LC-3β cells were established by stably
transfecting EGFP-LC3β cDNA into I45 or A549 parental
cells. I45 EGFP-LC-3β and A549 EGFP-LC-3β cells were
treated with 5 μM JY-1-106 for 12 hours. No aggregation of
EGFP-LC-3β, which indicates the formation of autophagy
or LC3 cleavage, was observed by fluorescent microscopic
examination or western blotting. Western blot analysis of
cleaved PARP further revealed that an overnight exposure
to 5 μM JY-1-106 resulted in PARP cleavage and cell death,
indicating apoptosis induction. In the A549 cells, significant
PARP cleavage and decreasing total PARP were observed
under exposure to 5 μM JY-1-106 regardless of Mcl-1
expression. However, PARP cleavage was observed in
ABT-737-treated A549 cells only upon transfection with
Mcl-1 siRNA (Figure 4A). Bax–Bax dimerization after
JY-1-106 treatment was observed in JY-1-106 treated
I45 cells (Figure 4B).
Figure 2 JY-1-106 functions as Bcl-xl and Mcl-1 pan-inhibitor. (A) JY-1-106 inhibits the binding of the Bak-BH3 α-helix to Mcl-1, as measured
by fluorescence polarization. The sequence of the fluorescently-labeled Bak peptide is FITC-Ahx-GQVGRQLAIIGDDINR-CONH2. (B) 5 × 10
6 REN cells
were exposed to 5 μM JY-1-106, 20 μM ABT-737 or a DMSO control for 12 hours and the cells were then harvested and lysed. Bcl- xL and Bak
were immunoprecipitated with specific antibodies. Bak signals and Bcl- xL signals were then detected by western blotting. These experiments
were repeated twice. (C) 5 × 106 REN cells were exposed to 5 μM JY-1-106, 20 μM ABT-737 or DMSO control for 12 hours and the cells were then
harvested and lysed. Mcl-1 and Bak were immunoprecipitated with specific antibodies. Bak signals and Mcl-1 signals were then detected by
western blotting. These experiments were repeated twice.
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Figure 3 JY-1-106 induces apoptosis in Mcl-1 overexpressed cancer cells. (A) Multiple cells lines grown under regular culture conditions
were collected and lysed. Bcl-xL and Mcl-1 expression in these cell lines were measured via western blotting. The β-actin expression levels were
detected to normalize for protein loading. (B) To determine the response of A549, DLD-1, DLD-1BR, H1299, H23, I45, I45BR and REN cells to
various chemotherapeutics including ABT-737, JY-1-106, cisplatin and SAHA, these cells were plated at a density of 3000 cells per well and treated
with different concentrations of these drugs over a 72 hour period. An XTT assay was then performed in quadruplicate for each treatment
condition. (C) REN and DLD-1 BR cells were transfected with control siRNA or Mcl-1 siRNA via electroporation. The cells were then seeded in 96
well plates and exposed to various doses of ABT-737. After 72 hours in culture, an XTT assay was performed to evaluate cell viability. This
experiment was repeated three times. The differences between these two groups were measured using the Student’s t-test (p < 0.01). Western
blotting of Mcl-1 was performed to evaluate Mcl-1 down-regulation in this experiment. (D) A549 and HMVEC cells were then seeded in 96 well
plates and exposed to various doses of JY-1-106. After 72 hours of culture, an XTT assay was performed in quadruplicate for each treatment
condition. The difference between A549 and HMVEC was compared using the Student’s t-test (p < 0.01). This experiment was repeated twice.
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membrane potential were measured by JC-1 staining
using fluorescence microscopy. Normally, the uptake of
JC-1 dye into mitochondria results in an intense red
fluorescence. When the mitochondrial membrane po-
tential is disrupted, the JC-1 dye migrates from the
mitochondria into cytoplasm and fluoresces with an
intense green signal. In our current study, A549 cells
were treated with JY-1-106 at concentrations of 5 μM
for 12 hours. As shown in Figure 4C, a significantly
reduced red fluorescence signal in mitochondria and asignificantly increased green fluorescent signal in the
cytosolic fraction were observed in the A549 cell line
following JY-1-106 exposure.
The JY-1-106-induced apoptosis was further evaluated
by a TUNEL assay. Flow cytometry was used to identify
and quantify apoptotic cells in JY-1-106‑treated cell
suspensions. A549 cells were treated with 5 μM JY-1-106
or DMSO for 24 hours, then subjected to a TUNEL
reaction and counterstained with propidium iodide. The
results indicate that treatment with JY-1-106, but not with
vehicle alone, results in a dramatic increase in the
Figure 4 JY-1-106 activates apoptosis via intrinsic pathway. (A) 5 × 106 A549 cells were transfected with Mcl-1 siRNAs or control siRNAs for
24 hours and then exposed to 5 μM JY-1-106 or 5 μM ABT-737 for 12 hours. Cleaved PARP and PARP proteins were then evaluated by western
blotting using anti-PARP antibodies. Immunoblotting for β-actin was performed to normalize the loading. (B) 5 × 106 I45 cells were exposed to
5 μM JY-1-106 or DMSO control for 12 hours. Bax and dimerized Bax were then assayed by western blotting using anti-Bax antibodies.
(C) Determination of mitochondrial membrane potential through JC-1 staining and detection using fluorescent microscopy. I45 cells were
exposed to 5 μM JY-1-106 or DMSO control for 12 hours. JC‑1 dye was then loaded into the medium for the final 20 minutes of culturing. After
JY-1-106 treatment, the mitochondrial membrane potential was found to be interrupted, as evidenced by the migration of JC‑1 dye from the
mitochondria into the cytoplasm of treated cells, and the subsequent reduction in the mitochondrial red fluorescence signals. (D) 2 × 106 A549
cells were exposed to 5 μM JY-1-106 or DMSO control for 12 hours. These cells were then collected, fixed and subjected to a TUNEL reaction.
Apoptosis signals were measured using flow-cytometry. The data shown are the average of triplicate assessments for each condition. The
differences between these two groups were measured using the Student’s t-test (p < 0.01). These experiments were repeated twice.
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sions (Figure 4D). Taken together, these results demon-
strate that JY-1-106 induces apoptosis in tumor cells.
JY-1-106 sensitizes tumor cells to chemotherapy and
metabolic stress
To explore the therapeutic potential of JY-1-106 in con-
junction with different chemotherapeutics, we evaluated
the use of Taxol in combination with JY-1-106 in the
A549 cell line to test for increased chemosensitivity. In
the JY-1-106 treatment of A549 cells, the cytotoxic
response to Taxol increased dramatically (Figure 5A).
Isobologram analysis was adopted to study the potential
synergism of cellular toxicity following a combination of
Taxol and JY-1-106 treatment. Isobologram analysis as-
sists in the determination of whether or not combinationFigure 5 JY-1-106 sensitized tumor cells to chemotherapy. (A and B) S
of JY-1-106 and Taxol. A549 cells were treated with JY-1-106 and Taxol at v
subsequently determined using the XTT assay. The results were converted
of three independent experiments. Synergy was determined by calculating
blot analysis of BH3-only proteins after Taxol treatment. A549 cells were ex
analyzed by western blotting using appropriate monoclonal and polyclona
apoptotic cells using an Annexin V binding assay. A549 cells were labeled
JY-1-106, Taxol or a combination of both for 12 hours. Cells were analyzed
three independent experiments.therapies are additive (CI = 1), synergistic (CI < 1) or an-
tagonistic (CI > 1). The CI values presented in Figure 5B
demonstrate that for all doses examined, the combina-
tions of Taxol and JY-1-106 were synergistic in A549
cells. A similar degree of sensitization was observed in
multiple cancer cell lines. Measuring BH3-only protein
expression in Taxol-treated cancer cells by western
blotting indicated that two BH3-only proteins, Bim and
PUMA, were significantly increased upon Taxol treat-
ments (Figure 5C), whilst others remain unchanged.
Annexin-V/flow cytometric analysis of A549 cells con-
firmed an increased sensitization with a combination of
Taxol and JY-1-106 by revealing that the percentage of
apoptotic cells was significantly higher when cells were
treated with both agents compared with individual treat-
ments (Figure 5D).ynergistic inhibition of cancer cell growth in vitro using a combination
arious concentrations. The viabilities of the treated cells were
to percentages of viable cells, and the data shown are representative
combination index (CI) values with Calcusyn software. (C) Western
posed to 5 nM Taxol for 12 or 24 hours. Cellular proteins were then
l antibodies specific for PUMA and Bim proteins. (D) Measurement of
with Annexin V‑FITC and counterstained with PI after exposure to
by flow cytometry. The final results were presented as the average of
Figure 6 JY-1-106 sensitizes tumor cells to metabolic stress. (A) A549 cells were exposed to metabolic stress and serial doses of JY-1-106.
After 72 hours, cell viability was measured using the XTT assay. The results shown are the average of triplicate assays and the experiment was
repeated twice. (B) A549 cells were subjected to metabolic stress with or without the addition of JY-1-106 for 48 hours. The same numbers of
viable cells were used for each time point. The intracellular ATP levels in these cells were measured fluorometrically. The differences between
these two groups at each time point were statistically evaluated using a Student’s t-test (p < 0.01). (C) Western blot analysis of BH3-only proteins
after metabolic stress. A549 cells were exposed to metabolic stress medium for 0, 1, 3, 6, 12 and 24 hours and analyzed by western blotting using
appropriate monoclonal and polyclonal antibodies specific for PUMA and Bim proteins. (D) Determination of apoptotic cells with the Annexin V
binding assay. A549 cells were labeled with Annexin V‑FITC and counterstained with PI after exposure to JY-1-106 or metabolic stress medium or
combination of JY-1-106 or metabolic stress medium for 24 hours. The cells were then analyzed by flow cytometry. The differences between
combination and JY-1-106 or TAXOL were measured using the Student’s t-test (p < 0.01). The final results presented are the average of three
independent experiments.
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could lead to decreased ATP production in metabolically
stressed cancer cells, A549 cells were exposed to a very
low dose of JY-1-106 in addition to metabolic stress. As
demonstrated in Figure 6A, significant cell death was
observed in the A549 cells treated with the combination
of metabolic stress medium and 0.25 μM JY-1-106,
which has little effect on cancer viability under regular
culture conditions. Decreased ATP production was quan-
titatively measured in A549 cells (Figure 6B). Measuring
BH3-only protein expression in cancer cells after meta-
bolic stress indicated that Bim and PUMA were signifi-
cantly increased upon 12 hours of metabolic stress
(Figure 6C). Annexin-V/flow cytometric analysis of A549
cells again confirmed an increased sensitization with a
combination of metabolic stress and 1 μM JY-1-106 byrevealing that the percentage of apoptotic cells was signifi-
cantly higher when cells were treated with both agents
compared with individual treatments (Figure 6D).
Inhibition of tumor growth by JY-1-106 in a lung cancer
xenograft model
To evaluate the effects of JY-1-106 in an animal model,
10 million A549 cells were injected intraperitoneally into
nude mice, and the tumors were allowed to grow for 20
days before any treatment was initiated. Following three
daily intraperitoneal administrations of JY-1-106 at 25 mg/
kg or vehicle control, each animal appeared to be in good
health. At necropsy, no gross signs of toxicity were found.
Intraperitoneally transplanted tumor samples were col-
lected and stained using the TUNEL assay. As demon-
strated in Figure 7A, JY-1-106, but not the vehicle control,
Figure 7 JY-1-106 inhibits tumor growth in lung cancer xenograft model. (A) Representative sections of organs and tumors collected from
mice injected daily for two days with JY-1-106 i.p. at 25 mg/kg in 500 μl of PBS or with a DMSO control. Tissues were preserved in formalin and
mounted in paraffin bocks. Tumor tissues were prepared using standard histology and TUNEL stained. TUNEL positive cells with brown color
were indicated with arrowhead. JY-1-106 treated tumors showed elevated numbers of apoptotic cells which were detectable by an increased
brown color. (B) Collected mouse tissues were preserved in formalin and mounted in paraffin bocks. Slides were prepared using standard
histology and stained with H&E. (C) Suppression of tumor growth in tumor‑bearing nude mice by JY-1-106. Nude mice were implanted with
tumor cells using s.c. injection in the right flanks. When the tumors reached 5 mm in diameter (2 weeks after injection), JY-1-106 was
administered at 25 mg/kg in 500 μl of PBS for each i.p. injection. DMSO alone was used as a mock treatment control. The injections were
performed every other day for seven sequential treatments. Tumor volumes were calculated from every-other daily measurements of tumor
diameters in all experimental and control groups. Results were reported as mean tumor volume ± SE over time (n = 6 mice for each treatment
and control group). The difference between the tumor volumes of the JY-1-106 treated mice versus tumor volumes of the solvent control treated
mice was significant (ANOVA test, p < 0.05). All of these experiments were repeated twice.
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thologic examination revealed no significant pathologic
lesions in the liver, kidney, lung and spleen (Figure 7B).
Chemical tests revealed normal BUN/creatinine levels in
each tumor-bearing mice suggesting that no nephrotoxicityresulted from the administration of JY-1-106. Tests that
evaluated liver function showed no elevation in transami-
nases or LDH in any of the animals. These results suggest
that JY-1-106 can be administered safely as there are no sig-
nificant toxicity effects.
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evaluated by administering this agent to nude mice
bearing flank human lung cancer xenografts. Tumor-
bearing mice were randomly divided into two treatment
groups, a vehicle control group and JY-1-106 therapy
group. The overall effects of these treatments on tumor
growth were analyzed using an ANOVA statistical
method. Treatment with JY-1-106 significantly inhibited
tumor growth in comparison to the vehicle control
(ANOVA test, p < 0.05; Figure 7C).
Discussion
The ability of anti-apoptotic proteins to promote cancer
cell survival depends on protein–protein interactions
between the BH3 domains of pro-apoptotic proteins and
the BH3-binding hydrophobic grooves of anti-apoptotic
proteins [2,20]. This interaction is defined by the binding
of the amphipathic α-helical BH3 domain from multi-
BH domain proteins, such as Bax and Bak, as well as
BH3 domain-only proteins, such as Bim, Bid, NOXA,
Bad and PUMA, to a hydrophobic pocket formed by the
BH1, BH2, and BH3 domains at the surface of anti-
apoptotic proteins, such as Bcl-2, Bcl-xL and Mcl-1. In
this way, the anti-apoptotic Bcl-2 proteins “neutralize”
the cell-killing function of their pro-apoptotic counter-
parts. This interaction prompted the idea that BH3 do-
main mimetics may serve as potential novel anti-cancer
drugs.
In this report, we characterize the novel α-helix mi-
metic JY-1-106 that disrupts the interactions between
both Bcl-xL and Mcl-1 with Bak, which leads to apop-
tosis through the mitochondrial pathway in human
cancer cells. Unlike several Bcl-2 antagonists such as
gossypol, apogossypolone, TW-37, obatoclax, ABT-737,
ABT-263, HA1–41, chelerythrine, antimycin and BHI-1,
JY-1-106 was designed using an α-helix mimicry strat-
egy involving a trisarylamide scaffold to spatially project
functionality in a manner similar to that of two turns of
the Bak -H3 domain α-helix. Specifically, JY-1-106 was
devised to reproduce the key hydrophobic side chains of
Val74, Leu78 and Ile81, all of which lie on one face of
the Bak-BH3 α-helix and have been shown to be critical
to mediating Bak’s protein–protein interactions [15]. Our
computational modeling studies suggest that JY-1-106
binds at the hydrophobic grove of anti-apoptotic pro-
teins such as Bcl-xL and Mcl-1 and engages amino acid
residues that are involved in binding to the Bak-BH3
α-helices of pro-apoptotic proteins. The control com-
pound JY-1-106a makes few favorable contacts leading
to increased fluctuations of the binding regions of both
Bcl-xL and Mcl-1, confirming that the side chains
attached to the trisarylamide scaffold are required for
interaction with Bcl-xL and Mcl-1. The FP assays and
IP western blotting results further supported theresults from our modeling study that JY-1-106 disrupts
Bcl-xL–Bak and Mcl-1–Bak interactions by binding to
the hydrophobic BH3-binding grooves on Bcl-xL and
Mcl-1. Collectively, these data convincingly suggest
that JY-1-106 is a pan-Bcl-2 inhibitor capable of antag-
onizing the two distinct subclasses of anti-apoptotic
proteins, Bcl-2/xL and Mcl-1, both of which are critical
for cancer cell survival. In fact, our animal study dem-
onstrated that JY-1-106 is active in vivo and could se-
lectively cause apoptosis in tumor cells and inhibit
tumor growth with limited damage to normal organs.
Our present results provide new insights into the
mechanisms of JY-1-106 mediated cell death. Our data
suggest that JY-1-106 induces programmed cell death
through the intrinsic apoptosis pathway. Pro-apoptotic
Bcl-2 proteins can be classified into two main groups:
multidomain pro-apoptotic proteins (Bax and Bak) and
BH3-only proteins (Bid, Bim, Bad, NOXA, PUMA, BMF,
BIK, and HRK) [21]. In response to death stimuli, certain
BH3-only proteins, the so-called sensitizers, displace
activators that include Bid and Bim from their inhibitory
associations with Bcl-xL or Mcl-1. The released activa-
tors induce the activation of Bax and Bak. ABT-737
functions like the BH3 domain peptide of Bad, binding
only the pro-survival Bcl-2 proteins Bcl-2 and Bcl-xL,
and acts as a sensitizing, but not as an activating, BH3
stimulus [22]. As Mcl-1 can antagonize Bax activation,
Mcl-1 overexpression contributes to the resistance to
ABT-737 [13]. Our current results suggest that the abil-
ities of JY-1-106 to bind both Mcl-1 and Bcl-xL contribute
to Bax activation in these cancer cells. Because JY-1-106
disrupts the interaction of anti-apoptotic proteins with
both of these multi-domain pro-apoptotic proteins, this
compound has important advantages, since several mech-
anisms have been proposed for Bcl-2 family-mediated can-
cer cell survival including direct and indirect pathways
that involve neutralization by anti-apoptotic proteins of
either multi-domain or BH3-only pro-apoptotic proteins.
Our present findings clearly revealed that JY-1-106
significantly sensitizes many types of tumor cells to
different chemotherapeutic agents or metabolic stress,
which may, in part, be due to a restoration of apoptotic
potential. Although JY-1-106 is active as a single agent
in tumor cells, it may be of clinical relevance for JY-1-106
to be used in combination with commonly used chemo-
therapeutic drugs. It has been shown that many chemo-
therapeutics, including 5-FU, vinblastine, and paclitaxel,
induce apoptosis by shifting the balance of proapoptotic to
antiapoptotic proteins at the mitochondria [23]. Proteins
containing BH3 domains are often the most dynamic par-
ticipants in this process. Our current results demonstrate
that both Bim and PUMA expression was induced by
Taxol treatment. The resulting data indicate that the
overexpression of anti-apoptotic members of the Bcl-2
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peutic agents through neutralization of these BH3-only
proteins, which could be overcome by using the pan Bcl-2
inhibitor JY-1-106.
We also observed that metabolically stressed cancer
cells are extremely sensitive to JY-1-106 treatment,
which can induce apoptosis at low dosages under these
conditions. It is well-established that Bcl-2 family anti-
apoptosis members protect metabolically stressed cancer
cells from apoptosis by neutralizing increases in PUMA
and Bim [24]. Since their BH3 domains have much
higher affinities to Bcl-xL/Bcl-2 or Mcl-1, elevated
PUMA and Bim levels can bind in an inhibitory manner
to Bcl-xL and Mcl-1. Overexpressed Bcl-xL and Mcl-1
in cancer cells, localized at the outer membrane of mito-
chondria, can prevent PUMA or Bim-related Bax activa-
tion and further prevent Bax-related mitochondrial
fission and apoptosis. In addition to their localization on
the mitochondrial outer membrane, Bcl-xL [25] and
Mcl-1 [26] were recently found to be localized within
mitochondria, where they functioned to promote ATP
generation rather than protect the cell against apoptosis.
These new functions of Bcl-xL and Mcl-1 were further
confirmed by our current observations that JY-1-106
causes significant reductions in ATP production, which
would also induce cell death. These data suggest that a
combination of JY-1-106 and a metabolic stress inducer
could be an effective anti-cancer treatment.
Conclusions
In summary, JY-1-106 displays single-agent activity in
multiple human cancer cells and in an animal tumor
model. This indicates that a strategy to disrupt protein–
protein interactions via α-helix mimicry using a substituted
trisarylamide scaffold was successful in developing a pan
Bcl-2 family antagonist. The mechanism of cell death in-
duced by JY-1-106 seems to be at least partially dependent
upon the mitochondrial apoptosis pathway, and our current
data support a process whereby this compound seems to
directly activate the Bax pro-apoptotic protein. These data
extend the knowledge of how BH3 agonists promote cell
death in cancer cells. Towards the discovery of more potent
and clinically-viable Bcl-2 antagonists, further development
of BH3 mimetics, which directly activate Bax/Bak, is
justified by our findings. Finally, our observations also




I45 and REN (human mesothelioma cell lines), A549,
H1299 and H23 (lung cancer cell lines) and DLD-1 and
HCT116 (colon cancer cell lines) were purchased from
the American Type Culture Collection (Manassas, VA).DLD-1, H1299, H23, I45 and REN cells were cultured in
RPMI 1640 medium supplemented with 10% fetal bovine
serum (FBS). A549 cells were cultured in 10% FBS-
supplemented F12 medium and HCT-116 cells in 10%
FBS-supplemented McCoy’s 5A medium. I45, A549,
DLD-1 and H23 have doubling time of 24 hours, while
REN can be doubled every 36 hours and H1299 cells can
be doubled every 18 hours.
Reagents
Cisplatin, 5-FU, Taxol and ABT-737 were obtained from
Selleck Chemicals (Houston, TX). The HDAC inhibitor
SAHA (suberoylanilide hydroxamic acid) was purchased
from Biovision (Mountain View, CA). Rabbit antibodies
against PARP, Bcl-xL and Mcl-1 were purchased from
Santa Cruz Biotechnology Inc. (Santa Cruz, CA). Mouse
monoclonal anti β-actin was obtained from Sigma (Saint
Louis, MO).
Molecular dynamics simulations
To study the binding of JY-1-106 to Bcl-xL and Mcl-1 at
a molecular level, molecular dynamics (MD) simulations
were performed using the CHARMM [27] and NAMD
[28] programs with the CHARMM22 protein force field
[15,25] and CHARMM General force field (CGenFF)
[29,30]. Modeling and MD simulations of Bcl-xL and
Mcl-1, initiated from PDB structures 1BXL and 3PK1,
respectively, involved the removal of the bound peptide
from each structure, the docking of JY-1-106 into the
hydrophobic binding pocket on the two proteins
followed by a 50 ns explicit solvent MD simulation. Both
forward (NH2 of JY-1-106 toward the N terminus of the
bound peptide) and backward orientations (vice versa)
of the compound in the binding pocket were considered.
A JY-1-106 analog (JY-1-106a as shown in Figure 1),
which lacks the isopropoxy side chains, was also simu-
lated with Bcl-xL and Mcl-1 to assess the importance of
the hydrophobic side chains on binding.
To quantitatively interpret the binding of the two
compounds, SILCS (Site Identification by Ligand Com-
petitive Saturation) simulations [17,31] on Bcl-xL and
Mcl-1 were performed. The crystal structures of the two
proteins (PDBID 3PL7 and 3PK1) were solvated in a
water box filled with 1 M benzene and 1 M propane
followed by MD simulations. Probability distributions
(FragMaps) were then used to identify regions on the
protein surface that are favorable for hydrogen bond
donors, hydrogen bond acceptors, aromatic groups and
aliphatic groups. FragMaps were converted into GFE
(grid free energy) maps. LGFE (ligand grid free energy)
[32] scores were evaluated for JY-1-106 in complex with
Bcl-xL and Mcl-1 using the bound ligand orientations
based on three approaches that take ligand and protein
flexibility into account. (1) 100 protein conformations
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and short, gas phase minimizations were performed for
the docked JY-1-106 conformations with the protein
fixed. The 100 minimized conformations were then used
for GFE scoring. (2) 10 complex conformations were
randomly selected from the first approach and a 100 ps
gas phase Langevin dynamics were performed for each
of the 10 conformations. During the simulation, both
the ligand and all protein atoms within 8 Å of the ligand
were allowed to move while other parts were fixed. 10
complex conformations were then selected from each
run, resulting in 100 structures for which the GFE scores
were calculated. (3) A 50 ns NPT MD simulation was
conducted with explicit considerations of water for the
complex and 100 structures were randomly extracted
and used for the GFE scoring. Presented are total LGFE
values for the full ligand and summed over all the aro-
matic or aliphatic side chain atoms for of the inhibitors.
Errors for the total LGFE values are standard errors over
the 100 conformations for each approach.
Fluorescence polarization assay
Fluorescence polarization experiments were conducted
using a BMG PHERAstar FS multimode microplate reader
equipped with two PMTs for simultaneous measurements
of perpendicular and parallel fluorescence emission
with 485 nm excitation and 520 nm emission filters
[19]. The Bak peptide was capped with fluorescein on
the N-terminus and was amidated on the C-terminus
(FITC-Ahx-GQVGRQLAIIGDDINR-CONH2). The assay
was performed in a black polypropylene 384-well
microplate (Costar) with a final volume of 20 μL containing
varying concentrations of Mcl-1 in the presence of 15 nM
FITC-Bak peptide in PBS at room temperature. The fluor-
escence polarization assays (FPCA) were performed using
100 nM Mcl-1 in the same buffer with varying concentra-
tions of JY-1-106. Regression analysis was carried out using
Origin (OriginLab, Northampton, MA) to fit the data to
the Hill equation (1) to determine the binding affinity
(Kd) of Mcl-1 for the binding of the FITC-Bak peptide
and to determine the IC50 in the FPCA. The Cheng-
Prusoff equation was then used to determine the Ki for
JY-1-106 as follows:




IC50, as determined using Hill equation; [LT
FITC-Bak],
total ligand (15 nM FITC-Bak); Kd
FITC-Bak, 20.81 ± 0.70
nM, being the affinity of Mcl-1 for FITC-Bak peptide
under the assay conditions.
Cell proliferation assays
The effects of various inhibitors on cell viability were
assessed in quadruplicate samples using the 2,3-bis(2-methoxy-4-nitro-5-sulfophenly)-5-[(phenylamino) car-
bonyl]-2H-tetrazolium hydroxide (XTT) assay (Trevigen,
Inc. Gaithersburg, MD). Cancer cells were seeded and
incubated in 96-well, flat-bottomed plates in 10% FBS-
supplemented culture medium 24 hours before drug
treatment. The cells were then exposed to various
inhibitors at the indicated concentrations at 37°C in 5%
CO2 for 72 hours. The medium was removed and
replaced with 150 μl fresh medium containing XTT, and
the cells were further cultured in the CO2 incubator at
37°C for 5 hours. Absorbance was determined on a plate
reader at 492 nm.JC-1 assay
The unique cationic dye JC-1 (5, 5′6, 6′-tetrachloro-1,
1′3, 3′-tetraethylbenzimidazolylcarbocyanine iodide) was
used to signal the loss of mitochondrial membrane po-
tential [33]. Cancer cell lines were exposed to JY-1-106
at 5 μM for 12 hours. Cells were then washed with PBS
and cultured with JC-1 dye for 15 minutes at 37°C in a
humidified atmosphere containing 5% CO2. Cells were
again washed with assay buffer. The loss of mitochon-
drial membrane potential was documented using an
Olympus IX71 fluorescent microscope fitted with FITC
and rhodamine filters.Western blotting analysis
Cancer cells were lysed using urea containing lysis buffer
and equal amounts of total proteins were resolved on
4-20% Tris-glycine gels and transferred onto a nitrocellu-
lose membrane. The membranes were then co-incubated
with a rabbit anti-human Bcl-xL polyclonal antibody, a
rabbit anti-human Mcl-1 monoclonal antibody, rabbit
anti-human PARP polyclonal antibody, and a mouse anti-
human β-actin antibody overnight. Antibody binding was
then detected using chemiluminescence (Cell Signaling
Technology, Danvers, MA) and signals were visualized by
autoradiography.Apoptosis assay
After various treatments, cancer cells were detected via
TUNEL assay using a FITC–TUNEL kit (Promega,
Madison, WI) and then measured with BD FACSCanto
II Flow cytometry. Flow cytometry data were analyzed
using FlowJo software (Tree Star Corp, Ashland, OR).ATP assay
The Cancer cells were initially treated with metabolic
stress medium with or without ABT-737 or JY-1-106 for
up to 24 hours. ATP was measured using the Fluorometric
ATP Assay Kit (Biovision, San Francisco, CA).
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Approval to conduct this study was obtained from the
Institutional Animal Care and Use Committees (IACUC)
at the Scott and White Memorial Hospital Texas Health
Science Center. This study was conducted in compliance
with institutional IACUC and NIH guidelines. To evaluate
the efficacy of JY-1-106, 2 × 106 A549 cells were injected
into the flank of female nude mice (6 weeks old). Once
the transplanted tumor reached 5 mm in diameter, mice
were treated with vehicle solution or JY-1-106 (25 mg/kg,
i.p., every other day for 2 weeks for a total of 7 injections).
Tumor sizes were measured three times per week until
reaching 1.5 cm in diameter. To further assess the imme-
diate effect of JY-1-106 in vivo, mice that had flank tumors
were injected i.p. with JY-1-106 (25 mg/kg) or vehicle so-
lution. Twenty-four hours after injection, the spleen, liver,
heart, lung and flank tumors were collected, fixed and
hematoxylin and eosin stained. Apoptosis in these samples
was determined using the TUNEL assay.
Statistical analysis
Continuous variables were compared using the Student’s
t test. The therapeutic relationship between JY-1-106
and Taxol was assessed with the CalcuSyn program,
based on the principle of Chou and Talalay. In the Chou
and Talalay method, the concentration-effect curve is
linearized by logarithmic transformation as follows:
log fu–1–1ð Þ ¼ log fa–1–1ð Þ–1 ¼ nlog Cð Þ–nlog Cmð Þ;
fu is the fraction of cells left unaffected after drug expos-
ure; fa is the fraction of cells affected by the exposure; C
is the drug concentration used; Cm is the concentration
that achieves the median effect; and n is the curve shape
parameter. Cm and n are equivalent to the IC50. The
values of n (obtained from the slope), nlog(Cm)
(obtained from the absolute value of the intercept), and,
therefore, Cm are obtained by plotting log(fu-1 - 1) versus
log(C).
The program returns the CI (combination index)
values that are indicative of synergism, additive effects,
or antagonism between two agents. CI analysis provides
qualitative information on the nature of drug interac-
tions, and CI, a calculated numerical value, also provides
a quantitative measure of the extent of drug interaction.
A CI of less than, equal to, and more than 1 indicates
synergy, additivity, and antagonism, respectively.
Immunohistochemistry
Formalin-fixed, paraffin-embedded tissues of lung adeno-
carcinoma and colon adenocarcinoma were examined for
the expression of Mcl-1 and Beclin-1 proteins. All samples
were histologically confirmed and de-identified. Approval
to conduct this study was obtained from the InstitutionalEthics Review Board at the Scott and White Memorial
Hospital Texas Health Science Center. This study was
conducted in compliance with the Helsinki Declaration.
The human colon cancer samples were stained using
an avidin-streptavidin-biotin-peroxidase kit (Vector
Laboratories).
Consent
Written informed consent was obtained from the patient
for publication of this report and any accompanying
images.
Additional file
Additional file 1: Figure S1. Mcl-1 and Bcl-xL expression patterns in
lung and colon adenocarcinomas. Lung adenocarcinoma and colon
adenocarcinoma tissue array slides were stained for Bcl-xL and Mcl-1
proteins using the ABC staining kit from Vector Lab. The co-existence of
Mcl-1 and Bcl-xL expression in tumor cells on the tissue slides was
assessed using the Fisher exact and Chi-square tests. Within each tumor
sample, both Mcl-1 and Bcl-xL expression in adjacent normal tissues was
very low. Neither Mcl-1 nor Bcl-xL expression was detected in the control
normal tissues included in these tissue arrays.
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